Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide

Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00250211

Enrollment

Registered

2005-11-08

Start date

2005-03-31

Completion date

2011-04-30

Last updated

2016-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma, Glioma

Keywords

magnetic resonance imaging, functional, radiation therapy, temozolomide, functional imaging, concurrent chemoradiation

Brief summary

The purpose of this study is to learn whether 3 tesla (3T) MRI functional imaging will map a tumor more accurately allowing a more targeted delivery of radiation. The investigators hope to learn whether tomotherapy will be able to deliver higher radiation doses safely to the tumor while sparing the surrounding normal tissue.

Interventions

PROCEDUREFunctional MRI imaging and tomotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Histologically confirmed glioblastoma multiforme * Ages 18-65 * Karnofsky Performance Scale (KPS) equal to or less than 70 * Minimal neurological deficit * Eligible for concurrent temozolomide chemotherapy

Exclusion criteria

* Prior radiation therapy to hand or neck area, chemotherapy, or radiosensitizer

Design outcomes

Primary

Measure	Time frame
determine tumor response and pattern of failure using functional MRI imaging	Study completion
time to disease progression	Study completion

Secondary

Measure	Time frame
distinguish residual tumor from treatment-related necrosis	study completion
survival	—
acute late toxicity of tomotherapy and hypofractionation	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026